Prenosis has announced the completion of a $20M Series A financing round alongside a $20M federal contract from the Biomedical Advanced Research and Development Authority (BARDA), bringing total new funding to $40M. The Chicago-based health technology company is focused on applying artificial intelligence and biological data to improve diagnosis and treatment in critical care settings, particularly for sepsis and severe respiratory infections.
The Series A round was led by PACE Healthcare Capital, with participation from Labcorp Venture Fund and Carle Health. The private capital is intended to support the commercial rollout of Sepsis ImmunoScore®, an FDA-authorized AI diagnostic designed to assess sepsis risk by combining biological markers with clinical data. Prenosis has positioned the tool as a way to identify high-risk patients earlier in their hospital course, supporting faster clinical decision-making during the early stages of disease progression.
“Because of these investments, we are well-positioned to advance the development of biology-driven solutions that can transform outcomes,” said Bobby Reddy, Jr., PhD, CEO of Prenosis.
While the venture funding emphasizes deployment and scale, the BARDA contract is directed toward treatment optimization. Awarded under BARDA’s Type to Treat Program, the $20M contract will fund a randomized controlled trial enrolling 800 patients with severe respiratory infections, including pneumonia and acute respiratory distress syndrome. The study will evaluate an AI-enabled “companion diagnostic” designed to predict which patients are likely to benefit from corticosteroid therapy.
Corticosteroids are widely used in critical care but remain controversial due to variable patient responses. Prenosis aims to use biological profiling to distinguish patients who may benefit from steroids from those who may experience harm, addressing what the company describes as the limitations of standardized treatment protocols.
In parallel, Prenosis plans to expand its Immunix™ platform into as many as 40 academic medical centers across the United States. This effort is intended to establish a precision medicine clinical trial network capable of rapidly identifying and enrolling patients based on specific biological characteristics. The company views this infrastructure as a foundation for future studies across multiple critical care conditions, supporting a broader shift toward data-driven, individualized treatment strategies.#
Click here for the original news story.